『Oncolytics Biotech (ONCY) Reports Durable Responses in RAS-Mutant Colorectal Cancer』のカバーアート

Oncolytics Biotech (ONCY) Reports Durable Responses in RAS-Mutant Colorectal Cancer

Oncolytics Biotech (ONCY) Reports Durable Responses in RAS-Mutant Colorectal Cancer

無料で聴く

ポッドキャストの詳細を見る

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 You’re listening to Spotrate Companies in Focus Oncolytics Biotech Symbol: NASDAQ:ONCY Oncolytics Biotech has reported promising durable responses in treating second-line RAS-mutant colorectal cancer, marking a notable advancement in its immunotherapy pipeline. | Powered by the Spotrate Terminal — delivering coverage of the global security markets.
まだレビューはありません